Chimeric CNS-targeting-peptide engineered exosomes for experimental autoimmune encephalomyelitis therapy
Ying-Kai Wang1, Yun-Peng Zhao2, Ming-Zhu Ye3
1School of Medicine, Guangxi University, Nanning, Guangxi, China.
International Immunopharmacology
|September 17, 2023
Summary
TAxI-exos, engineered exosomes from umbilical cord mesenchymal stem cells, show enhanced CNS accumulation and therapeutic effects for multiple sclerosis (MS) models. These modified exosomes effectively reduced inflammation and promoted neuroprotection in experimental autoimmune encephalomyelitis (EAE).
Area of Science:
- Neuroscience
- Immunology
- Biotechnology
Background:
- Multiple sclerosis (MS) is a CNS inflammatory disease causing demyelination and neuronal damage, with no current cure.
- Exosomes from umbilical cord mesenchymal stem cells (UMSCs) show therapeutic potential for MS models but suffer from poor CNS accumulation.
- Targeted delivery of therapeutic agents to the CNS remains a significant challenge in treating neurological disorders.
Purpose of the Study:
- To develop and evaluate TAxI-exos, UMSC-derived exosomes engineered for enhanced CNS accumulation and therapeutic efficacy in experimental autoimmune encephalomyelitis (EAE).
- To investigate the mechanism of action of TAxI-exos in modulating immune responses and reducing neuroinflammation in vitro and in vivo.
Main Methods:
- TAxI-peptide-chimeric UMSC-exosomes (TAxI-exos) were developed and administered to EAE mice.
- In vivo studies involved analyzing spinal cords, spleens, and blood for demyelination, inflammation, microglia, T-cell subsets, and cytokine expression.
- In vitro studies utilized T cells and BV-2 microglial cells to assess immune modulation, targeting ability, and polarization.
Main Results:
- TAxI-exos demonstrated significantly improved therapeutic effects in EAE mice compared to unmodified UMSC-exosomes, attributed to enhanced CNS targeting.
- Treatment with TAxI-exos reduced T-cell infiltration, inflammation, and pro-inflammatory microglia (M1), while promoting anti-inflammatory microglia (M2) polarization via the TNF pathway.
- TAxI-exos modulated cytokine expression, upregulating IL-4, IL-10, TGF-β, and IDO-1, and downregulating IL-2, IL-6, IL-17A, IFN-γ, and TNF-α.
Conclusions:
- Engineered TAxI-exos exhibit significant CNS-targeting properties and potent therapeutic effects in an EAE model.
- The findings suggest TAxI-exos can inhibit degenerative processes and modulate immune responses, offering potential therapeutic value for MS and other CNS disorders.
- This approach highlights the promise of exosome engineering for overcoming delivery barriers in treating complex neurological diseases.
